The Journal of allergy and clinical immunology · 2026
IFN-γ-driven CD8+ T-cell-keratinocyte cross talk underlies inflammation and blistering in pemphigus lesions.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Yiting, Xu Chuqiao, Wang Qijun, Huang Zixuan, Ke Huiyi, Zhang Wenqian, Zhang Tianyu, Ruan Yue, Zhao Wenzhe, Wang Hailun, Wang Jingying, Zhu Haiqin, Huang Chuanxin, Pan Meng
Аннотация
BACKGROUND: Pemphigus is an autoimmune bullous disease primarily driven by anti-desmoglein (Dsg) autoantibodies. However, the disease pathogenesis beyond anti-Dsg autoantibodies remains unclear.
OBJECTIVE: We sought to explore the pathogenic role of IFN-γ in pemphigus and to evaluate the therapeutic potential of targeting the IFN-γ-JAK pathway.
METHODS: The pathogenetic effects of IFN-γ signaling in pemphigus were investigated by integrated single cell analysis, ex vivo human skin explants, and cocultures. Therapeutic efficacy of the JAK1 inhibitor abrocitinib was evaluated in a murine pemphigus model and in refractory pemphigus patients.
RESULTS: IFN-γ-expressing T cells largely infiltrate pemphigus lesions and drive IFN-γ-dominant inflammation. IFN-γ-activated keratinocytes secrete C-X-C motif chemokines CXCL9/10/11 to recruit more CD8+ T cells. Notably, IFN-γ primes keratinocytes to become more susceptible to CD8+ T-cell-mediated cytotoxicity. Moreover, IFN-γ synergizes with anti-Dsg autoantibodies to induce keratinocyte dissociation through p38 activation and augments anti-Dsg autoantibody production. Oral JAK1 inhibitor abrocitinib effectively attenuated IFN-γ-dominant inflammation and improved skin lesions in a murine pemphigus model and in patients with refractory disease.
CONCLUSION: A self-amplifying inflammatory circuit between IFN-γ+CD8+ T cells and keratinocytes acts as a key driver of pemphigus pathogenesis and provides a mechanistic rationale for targeting the IFN-γ-JAK pathway in its treatment.
OBJECTIVE: We sought to explore the pathogenic role of IFN-γ in pemphigus and to evaluate the therapeutic potential of targeting the IFN-γ-JAK pathway.
METHODS: The pathogenetic effects of IFN-γ signaling in pemphigus were investigated by integrated single cell analysis, ex vivo human skin explants, and cocultures. Therapeutic efficacy of the JAK1 inhibitor abrocitinib was evaluated in a murine pemphigus model and in refractory pemphigus patients.
RESULTS: IFN-γ-expressing T cells largely infiltrate pemphigus lesions and drive IFN-γ-dominant inflammation. IFN-γ-activated keratinocytes secrete C-X-C motif chemokines CXCL9/10/11 to recruit more CD8+ T cells. Notably, IFN-γ primes keratinocytes to become more susceptible to CD8+ T-cell-mediated cytotoxicity. Moreover, IFN-γ synergizes with anti-Dsg autoantibodies to induce keratinocyte dissociation through p38 activation and augments anti-Dsg autoantibody production. Oral JAK1 inhibitor abrocitinib effectively attenuated IFN-γ-dominant inflammation and improved skin lesions in a murine pemphigus model and in patients with refractory disease.
CONCLUSION: A self-amplifying inflammatory circuit between IFN-γ+CD8+ T cells and keratinocytes acts as a key driver of pemphigus pathogenesis and provides a mechanistic rationale for targeting the IFN-γ-JAK pathway in its treatment.